Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease
- 3 May 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 75 (7), 1772-1777
- https://doi.org/10.1093/jac/dkaa152
Abstract
Background Remdesivir has received significant attention for its potential application in the treatment of COVID-19, caused by SARS-CoV-2. Remdesivir has already been tested for Ebola virus disease treatment and found to have activity against SARS and MERS coronaviruses. The remdesivir core contains GS-441524, which interferes with RNA-dependent RNA polymerases alone. In non-human primates, following IV administration, remdesivir is rapidly distributed into PBMCs and converted within 2 h to the active nucleoside triphosphate form, while GS-441524 is detectable in plasma for up to 24 h. Nevertheless, remdesivir pharmacokinetics and pharmacodynamics in humans are still unexplored, highlighting the need for a precise analytical method for remdesivir and GS-441524 quantification. Objectives The validation of a reliable UHPLC-MS/MS method for remdesivir and GS-441524 quantification in human plasma. Methods Remdesivir and GS-441524 standards and quality controls were prepared in plasma from healthy donors. Sample preparation consisted of protein precipitation, followed by dilution and injection into the QSight 220 UHPLC-MS/MS system. Chromatographic separation was obtained through an Acquity HSS T3 1.8 μm, 2.1 × 50 mm column, with a gradient of water and acetonitrile with 0.05% formic acid. The method was validated using EMA and FDA guidelines. Results Analyte stability has been evaluated and described in detail. The method successfully fulfilled the validation process and it was demonstrated that, when possible, sample thermal inactivation could be a good choice in order to improve biosafety. Conclusions This method represents a useful tool for studying remdesivir and GS-441524 clinical pharmacokinetics, particularly during the current COVID-19 outbreak.Funding Information
- European Union (RIA2018EF-083)
This publication has 24 references indexed in Scilit:
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitroCell Research, 2020
- Drug treatment options for the 2019-new coronavirus (2019-nCoV)BioScience Trends, 2020
- A Randomized, Controlled Trial of Ebola Virus Disease TherapeuticsThe New England Journal of Medicine, 2019
- Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading ExoribonucleasemBio, 2018
- Matrix effect management in liquid chromatography mass spectrometry: the internal standard normalized matrix effectBioanalysis, 2017
- Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronavirusesScience Translational Medicine, 2017
- Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging VirusesJournal of Medicinal Chemistry, 2017
- CLSI C62-A: A New Standard for Clinical Mass SpectrometryClinical Chemistry, 2016
- UHPLC–MS/MS method with automated on-line solid phase extraction for the quantification of entecavir in peripheral blood mononuclear cells of HBV+ patientsJournal of Pharmaceutical and Biomedical Analysis, 2015
- Stability and inactivation of SARS coronavirusMedical Microbiology and Immunology, 2004